MacroGenics Inc. (MGNX) Shares Down 0.9%
MacroGenics Inc. (NASDAQ:MGNX) shares fell 0.9% during trading on Tuesday . The company traded as low as $31.42 and last traded at $31.50, with a volume of 119,132 shares trading hands. The stock had previously closed at $31.80.
A number of research firms recently commented on MGNX. Morgan Stanley reiterated a “hold” rating on shares of MacroGenics in a research note on Thursday, June 30th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of MacroGenics in a research note on Tuesday, June 14th. Leerink Swann restated an “outperform” rating and set a $47.00 target price on shares of MacroGenics in a report on Thursday, May 19th. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Finally, Citigroup Inc. cut shares of MacroGenics from a “buy” rating to a “neutral” rating and raised their target price for the stock from $27.00 to $32.00 in a report on Thursday, August 4th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $38.71.
The stock’s market capitalization is $1.09 billion. The company has a 50-day moving average price of $29.46 and a 200-day moving average price of $22.83.
MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $1.14. The firm earned $80.67 million during the quarter, compared to the consensus estimate of $27.22 million. During the same period in the previous year, the company posted ($0.71) EPS. The firm’s revenue for the quarter was up 1100.4% on a year-over-year basis. On average, equities research analysts forecast that MacroGenics Inc. will post ($1.29) earnings per share for the current fiscal year.
In other news, SVP Jon Marc Wigginton sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $30.78, for a total value of $615,600.00. Following the completion of the transaction, the senior vice president now owns 20,000 shares in the company, valued at $615,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Lynn Cilinski sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the transaction, the vice president now owns 6,923 shares of the company’s stock, valued at approximately $173,075. The disclosure for this sale can be found here.
Several hedge funds and institutional investors recently added to or reduced their stakes in MGNX. Marshall Wace LLP boosted its position in MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock valued at $2,902,000 after buying an additional 45,422 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its position in MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock valued at $1,386,000 after buying an additional 20,929 shares during the period. Finally, Jennison Associates LLC boosted its position in MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock valued at $8,282,000 after buying an additional 909 shares during the period.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.